Construction of hollow polydopamine nanoparticle based drug sustainable release system and its application in bone regeneration.
10.1038/s41368-021-00132-6
- Author:
Lu WANG
1
;
Shuwei LIU
2
;
Chunxia REN
1
;
Siyuan XIANG
2
;
Daowei LI
3
;
Xinqing HAO
1
;
Shilei NI
3
;
Yixin CHEN
2
;
Kai ZHANG
4
;
Hongchen SUN
5
Author Information
1. Department of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, China.
2. State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, China.
3. Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, School and Hospital of Stomatology, Jilin University, Changchun, China.
4. State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, China. zk@jlu.edu.cn.
5. Department of Oral Pathology, Hospital of Stomatology, Jilin University, Changchun, China. hcsun@jlu.edu.cn.
- Publication Type:Research Support, Non-U.S. Gov't
- MeSH:
Animals;
Bone Regeneration;
Indoles;
Nanoparticles;
Osteogenesis;
Pharmaceutical Preparations;
Polymers;
Rats
- From:
International Journal of Oral Science
2021;13(1):27-27
- CountryChina
- Language:English
-
Abstract:
Nanomaterial-based drug sustainable release systems have been tentatively applied to bone regeneration. They, however, still face disadvantages of high toxicity, low biocompatibility, and low drug-load capacity. In view of the low toxicity and high biocompatibility of polymer nanomaterials and the excellent load capacity of hollow nanomaterials with high specific surface area, we evaluated the hollow polydopamine nanoparticles (HPDA NPs), in order to find an optimal system to effectively deliver the osteogenic drugs to improve treatment of bone defect. Data demonstrated that the HPDA NPs synthesized herein could efficiently load four types of osteogenic drugs and the drugs can effectively release from the HPDA NPs for a relatively longer time in vitro and in vivo with low toxicity and high biocompatibility. Results of qRT-PCR, ALP, and alizarin red S staining showed that drugs released from the HPDA NPs could promote osteogenic differentiation and proliferation of rat bone marrow mesenchymal stem cells (rBMSCs) in vitro. Image data from micro-CT and H&E staining showed that all four osteogenic drugs released from the HPDA NPs effectively promoted bone regeneration in the defect of tooth extraction fossa in vivo, especially tacrolimus. These results suggest that the HPDA NPs, the biodegradable hollow polymer nanoparticles with high drug load rate and sustainable release ability, have good prospect to treat the bone defect in future clinical practice.
